- Home
- CARM vs BIAF Comparison
CARM vs BIAF Comparison
Compare CARM & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- BIAF
- Stock Information
- Founded
- CARM 2016
- BIAF 2014
- Country
- CARM United States
- BIAF United States
- Employees
- CARM N/A
- BIAF N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CARM Health Care
- BIAF Health Care
- Exchange
- CARM Nasdaq
- BIAF Nasdaq
- Market Cap
- CARM 17.4M
- BIAF 14.5M
- IPO Year
- CARM N/A
- BIAF 2022
- Fundamental
- Price
- CARM $0.44
- BIAF $0.68
- Analyst Decision
- CARM Hold
- BIAF Strong Buy
- Analyst Count
- CARM 5
- BIAF 1
- Target Price
- CARM $4.57
- BIAF $6.00
- AVG Volume (30 Days)
- CARM 277.1K
- BIAF 313.4K
- Earning Date
- CARM 11-07-2024
- BIAF 11-14-2024
- Dividend Yield
- CARM N/A
- BIAF N/A
- EPS Growth
- CARM N/A
- BIAF N/A
- EPS
- CARM N/A
- BIAF N/A
- Revenue
- CARM $20,268,000.00
- BIAF $9,367,785.00
- Revenue This Year
- CARM $46.34
- BIAF $285.51
- Revenue Next Year
- CARM N/A
- BIAF $20.05
- P/E Ratio
- CARM N/A
- BIAF N/A
- Revenue Growth
- CARM 41.13
- BIAF 2813.87
- 52 Week Low
- CARM $0.38
- BIAF $0.66
- 52 Week High
- CARM $2.77
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- CARM 37.99
- BIAF 26.89
- Support Level
- CARM $0.42
- BIAF $0.67
- Resistance Level
- CARM $0.48
- BIAF $1.01
- Average True Range (ATR)
- CARM 0.06
- BIAF 0.08
- MACD
- CARM 0.01
- BIAF -0.01
- Stochastic Oscillator
- CARM 18.67
- BIAF 4.29
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.